Septerna (SEPN) drew fresh attention after first quarter 2026 results showed sales of US$26.52 million and a narrower net loss of US$8.64 million. Analysts view these developments as progress toward breakeven.

The stock has been volatile around these results, with a 1-day share price return showing a 4.84% decline after the earnings release, a 7-day share price return showing a 12.90% gain, and a 1-year total shareholder return of about 1.7x, which points to strong longer term momentum despite some recent pullback.

If Septerna’s move has caught your eye, this could be a good moment to see what else is gaining attention in healthcare, starting with 32 healthcare AI stocks

With Septerna trading at US$26.95 against an analyst price target of US$44.25, the stock sits at a steep discount. Are you looking at an underappreciated opportunity, or a market already pricing in future growth?

Price-to-Sales of 16.8x: Is It Justified?

On the current numbers, Septerna trades on a P/S of 16.8x, which looks rich when you set it against both industry and peer benchmarks.

The P/S ratio compares the company’s market value to its revenue, so for every dollar of GPCR oral small molecule revenue Septerna generates, the market is pricing in $16.80. For early stage biotech, investors often focus on pipeline potential and milestones rather than current profits, which can support higher P/S levels even while the company remains loss making.

Here, that premium is not small. The P/S of 16.8x is more than triple the US Pharmaceuticals industry average of 5.4x and also more than double the peer average of 7.7x. Compared with an estimated fair P/S of 4.4x, the current multiple sits well above the level that regression analysis suggests the market could move toward if sentiment cools.

Result: Price-to-Sales of 16.8x (OVERVALUED)

However, there are clear watchpoints here, including ongoing net losses of US$36.04 million and annual revenue growth that currently indicates a slight decline.

Next Steps

Seen enough to form a view, or still on the fence about whether the current optimism is warranted? Take a closer look at the details, compare the risks to your own expectations, and see why many investors are focusing on 2 important warning signs.

Looking for more investment ideas?

If Septerna has sharpened your interest, do not stop here. Widen your watchlist now so you are not chasing the next opportunity after it has run.

• Spot potential value opportunities early by checking companies that feature in the 50 high quality undervalued stocks.
• Prioritise resilience by reviewing stocks highlighted in the 66 resilient stocks with low risk scores.
• Hunt for lesser known prospects by scanning the screener containing 22 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.